Advanced search

News (90)

Transcript : Novo Nordisk A/S - Shareholder/Analyst Call	21/03
Novo Nordisk hopes to launch experimental obesity drug this decade	08/03	RE
Novo Nordisk CEO says innovation in obesity may justify higher price in some segments	08/03	RE
Novo's global obesity drug rollout to be dominated by injectable medicines, CEO says	07/03	RE
Transcript : Novo Nordisk A/S - Analyst/Investor Day	07/03
Novo Nordisk CEO Jorgensen: Demand will outstrip supply for years to come	08/02	MT
Novo Nordisk doesn't disappoint	31/01
As Lilly competition heats up, Novo CEO details strategy for new Wegovy launches	31/01	RE
Transcript : Novo Nordisk A/S, 2023 Earnings Call, Jan 31, 2024	31/01
Jorgensen, CEO of Novo Nordisk: €10bn investment to meet demand for its weight loss drugs	31/01	MT
Catalent's Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo	31/01	RE
Novo Nordisk sees double-digit FY growth; boosts Wegovy supplies to U.S	31/01	RE
Novo Nordisk Begins Gradually Increasing Supply of Blockbuster Weight-Loss Drug Wegovy -- Update	31/01	DJ
Novo Nordisk will more than double U.S. lower doses of Wegovy, CEO says	31/01	RE
Novo Nordisk sees double-digit FY growth as Q4 profit beats estimate	31/01	RE
Novo CEO expects patients to stay on Wegovy longer than older weight loss drugs	10/01	RE
Transcript : Novo Nordisk A/S Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM	09/01
Novo Nordisk invests $2.3 bln in France to boost obesity drug production	23/11	RE
Novo Nordisk Seeks Bolt-On Acquisitions	10/11	CI
Drugmaker Novo Nordisk seeks obesity, diabetes 'bolt-on' deals	10/11	RE
Novo Nordisk prefers "bolt-on" acquisitions, not large deals, CEO says	10/11	RE
EU proposal may accelerate pharma innovation decline, industry group says	06/11	RE
Lars Fruergaard Jorgensen, CEO of Novo Nordisk: dose limitation to continue until 2024	02/11	MT
Wegovy launch in UK may underline Novo's need to get ahead of Lilly	10/23/10	RE
Novo CEO on Ozempic, Wegovy Demand, Acquisition Strategy	01/23/01	MT
Catalent's Indiana plant to make Novo's Wegovy weight-loss drug-sources	25/23/25	RE
Novo Nordisk A/S : "With obesity, we're dealing with a billion patients worldwide".	25/23/25
Novo Nordisk CEO Lars Fruergaard Jorgensen at Reuters Newsmaker event	25/23/25	RE
Novo says Wegovy drug helps obese people with heart failure in trial	25/23/25	RE
Novo Nordisk tells Europe weight-loss drug will save money as well as lives	25/23/25	RE
Novo Nordisk to launch Wegovy in more countries in 'constrained' manner - CEO	25/23/25	RE
Novo Nordisk CEO 'confident' Catalent will overcome Wegovy production problems	25/23/25	RE
Novo Nordisk to address social inequality in dialogue with healthcare systems -CEO	25/23/25	RE
INTERVIEW - Lars Fruergaard Jorgensen, CEO of Novo Nordisk: Treating obesity will be one of our top healthcare priorities	10/23/10	MT
Novo Nordisk CEO: US limits on weight-loss Wegovy use likely to last into 2024	10/23/10	RE
Europe faces long wait for weight-loss drugs as governments eye costs	10/23/10	RE
Novo Nordisk: Wegovy launch in new markets will be slower than planned due to high demand	20/23/20	RE
Novo Nordisk Reports Surging Demand for Diabetes, Obesity Drugs Ozempic and Wegovy	04/23/04	DJ
Transcript : Novo Nordisk A/S - Shareholder/Analyst Call	23/23/23
Novo Nordisk Sees Strong Demand for Obesity Drug	08/23/08	MT
Transcript : Novo Nordisk A/S, 2022 Earnings Call, Feb 01, 2023	01/23/01
Novo Nordisk to increase manufacturing capacity of weight-loss drugs	02/22/02	RE
Novo Nordisk sees faster profit growth on demand for diabetes drug Ozempic	02/22/02	RE
Transcript : Novo Nordisk A/S Presents at JP Morgan EU Healthcare CEO Conference Calls Series 2022, Sep-14-2022 02:00 PM	14/22/14
Obesity drug supply delay not unusual says Novo Nordisk CEO	04/22/04	RE

123NextSee all

Companies (4)

LAR ESPAÑA REAL ESTATE SOCIMI, S.A. 654 M $

Lar Espana Real Estate SOCIMI SA is a Spain-based company primarily engaged in the operation of retail Real Estate Investment Trusts (REITs). The Company specializes in acquiring, managing and renting real estate assets within the Spanish market. Its busi ...

VIMAB GROUP AB 20 M $

VIMAB Group AB (publ), formerly known as Headsent AB (publ), is a Sweden-based industrial group consisting of eight companies such as: Bess, Lars lap, Sanocon, SteamBox, Tanktech, Tottes Welding & Industrial Assembly and VIMAB, active in environmental and ...

KELTECH ENERGIES LIMITED 50 M $

Keltech Energies Limited is an India-based company engaged in the manufacturing of industrial explosives and sale of perlite and perlite-based products. The Company is engaged in manufacturing cartridge explosives, bulk emulsion explosives, mono methyl am ...

TRISUL S.A. 172 M $

Trisul SA is a Brazil-based company involved in the real estate sector. It was founded as a result of a merger between two companies: Incosul Incorporacao e Construcao Ltda and Tricury Construcoes e Participacoes Ltda. Together with its subsidiaries, the ...

Insiders

Lars Fruergaard Jorgensen

Mr. Lars Fruergaard Jørgensen is a Vice President at European Federation of Pharmaceutical Industries & Assns, a Vice Chairman-Supervisory Board at Carlsberg A/S, a Member-Supervisory Board at Carlsberg Breweries A/S, a President & Chief Executive Officer at Novo Nordisk Ltd., a President & Chief Executive Officer at Novo Nordisk A/S and a Chairman at Harno Invest A/S. He is on the Board of Directors at Carlsberg A/S and Carlsberg Breweries A/S. Mr. Jørgensen was previously employed as a Member-Supervisory Board by Innate Pharma SA, a Vice President-Finance & Information Technology by Novo Nordisk Pharmaceutical SAS, and a Chairman by NNE Pharmaplan A/S. He also served on the board at ZymoGenetics, Inc. and NNIT A/S. He received his graduate degree from the University of Aarhus.